By Caroline Copley ZURICH (Reuters) - Novartis raised its full-year outlook on Wednesday after generic competition to its best-selling blood pressure pill was delayed, granting the Swiss drugmaker a temporary reprieve from patent losses. The Basel-based firm lost its patent rights on Diovan in the United States last year and faced competition from a copycat version of its monotherapy from Ranbaxy Laboratories . But the lab has so far failed to get a green light for production from U.S. regulators. ...
Related Articles
http://myteendating.com/index.php?do=/blog/1634/the-benefits-of-applying-safe-diet-supplements/
http://moghreor.jigsy.com/entries/general/Weight-Loss-Secrets-That-Work
http://min-gle.com/blogs/2687/2851/alarming-opinions-about-all-natu
http://moasouthflorida.com/blog/11464/the-intents-behind-natural-weight-loss-products/
No comments:
Post a Comment